Kamile Kırca, Ozlem Yurtal, Sevinc Kutluturkan

Opinions and Experiences of Patients Receiving Oral Chemotherapy: A Qualitative Study

Aim: This study is a qualitative study aimed to determine the opinions and experiences of patients receiving oral chemotherapy. Methods: The study was conducted in January 2018 with 18 volunteers who applied to oncology polyclinic at a university hospital and received oral chemotherapy. In data collection, a description form and a semi-structured interview form were administered. In data analysis process, transcription after each interview and evaluation steps through thematic content analysis method were employed. Results: The themes obtained in the study are as access to drugs, use of medicine, side effects and control of treatment, approach of health professionals and support of family and relatives. There is a need to ensure the continuity of the treatment follow-up period in order to improve treatment compliance of patients, to monitor side effects of treatment and to ensure safe use of medicines. Conclusion:In this process, it is crucial that nurses take an active role in patient education and counselling among health professionals so that weaknesses in the patient's drug use process and opportunities for improvement could be identified.

Keywords:

Oral chemotherapy agents patient, qualitative study, experience,

PDF

___

[1] Özkaraman A, Orlu N, Atalay H, Babadağ B, Yılmaz H, Dinçer M, Alparslan G.B. Assessment of problems and medication adherence of patients taking oral chemotherapy Medical Journal of Bakırköy. 2017;13: 91-97. https://doi: 10.5350/BTDMJB201713206 (Turkish)
[2] Bedell CH. Changing Paradigm for Cancer Treatment: The Advent of New Oral Chemotherapy Agents. Clinical Journal of Oncology Nursing. 2003;7:5–9.https://doi: 10.1188/03.CJON.S6.5-9
[3] Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C. Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer. 2010;18:583-590. https://doi: 10.1007/s00520-009-0692-5
[4] Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26:61-69. https://doi: 10.1185/03007990903396469.
[5] Collins CM, Elsaid KA. Using an enhanced oral chemotherapy computerized provider order entry system to reduce prescribing errors and improve safety. Int J Qual Health Care. 2011;23:36-43. https:// doi: 10.1093/intqhc/mzq066.
[6] Kav S, Bostancı H. Role of the nurse in patient education and follow up of people receiving oral chemotherapy treatment in Turkey. Support Care Cancer. 2006; 14: 1252-1257. https:// doi: 10.1007/s00520-007-0377-x
[7] Barillet M, Prevost V, Joly F, Clarisse B. Oral antineoplastic agents: How do we care about adherence? Br J Clin Pharmacol. 2015; 80:1289-1302. https://doi: 10.1111/bcp.12734
[8] Bettencourt E. Oral Chemotherapy– What Your Patıents Need To Know. 2014. Access date: 08.01.2018 http://www.accc-cancer.org/
[9] Moody M, Jackowski J. Are patients on oral chemotherapy in your practice setting safe? Clin J Oncol Nurs. 2010;14:339-346. https://doi:10.1188/10.CJON.339-346.
[10] Wood L. A review on adherence management in patients on oral cancer therapies. European Journal of Oncology Nursing. 2012;16:432-438. https://doi: 10.1016/j.ejon.2011.10.002
[11] Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59: 56-66. https://doi: 10.3322/caac.20004.
[12] Johnson PE, Chambers CR, Vaida AJ. Oncology medication safety: A 3D status report 2008. J Oncol Pharm Pract. 2008;14:169– 180. https://doi: 10.1177/1078155208097634
[13] Chan A, Leow YC, Sim H. Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center. J Oncol Pharm Pract. 2009;15:161– 165. https://doi: 10.1177/1078155208100584
[14] Bartel SB. Safe Practices And Financial Considerations In Using Oral Chemotherapeutic Agents, Am J Health-Syst Pharm. 2007; 64:8-14. https://doi.org/10.2146/ajhp070036
[15] Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw.2008; 3:1-14.
[16] Lester J. Safe handling and administration considerations of oral anticancer agents in the clinical and home setting. Clin J Oncol Nurs. 2012;16:92-197. https://doi: 10.1188/12.CJON.E192-E197
[17] Cassidy J, Twelves C, Van Cutsem E, Hoff B, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology. 2002;13:566-575. https://doi.org/10.1093/annonc/mdf089
[18] Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652-61. https://doi.org/10.1093/jnci/94.9.652
[19] Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157:785-95. https://doi: 10.7326/0003-4819-157-11-201212040-00538
[20] Halfdanarson TR, Jatoi A. Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep. 2010;12:247-52. https://doi: 10.1007/s11912-010-0103-6.
[21] Kav S, Johnson J, Rittenberg C, Fernadez-Ortega P, Suominen T, Olsen PR, et al. Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer. 2008;16:1075-83. https://doi: 10.1007/s00520-007-0377-x
[22] Sözeri E, Kutlutürkan S. Key Element in Oral Chemotherapy: Patient Adherence Medical Journal of Bakırköy. 2016: 23, 290-293. https://doi: 10.5505/vtd.2016.43027 (Turkish)
[23] Banna GL, Collovà E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev. 2010;36:595-605. https://doi: 10.1016/j.ctrv.2010.04.005
[24] Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–115. https://doi: 10.1200/JCO.1997.15.1.110
[25] Cass Y, Setton I. 25 Years Of Safe Handling Of Cytotoxics (Antineoplastics) In Israel, J Oncol Pharm Practice. 2006;12: 83-90. https://doi.org/10.1177/1078155206069159
[26]American Society of clinical Oncology. Oral Chemotherapy. (2017). https://www.cancer.net/sites/cancer.net/files/asco_answers_oral_chemotherapy.pdf
[27] Aslan Ö, Vural H, Kömürcü Ş, Özet A. Effect of Education On Chemotherapy Symptoms in Cancer Patients Receiving Chemotherapy, C.Ü. Hemşirelik Yüksekokulu Dergisi. 2006;10: 15-28 (Turkish)
[28] Simchowitz B, Shiman L, Spencer J, Brouillard D, Gross A, Connor M, et al. Perceptions and Experiences With Oral Chemotherapy. Clinical Journal of Oncology Nursing. 2010;14:447-453. https://doi: 10.1188/10.CJON.447-453.
[29] Battle JF, Arranz EE, Carpeno JC, Saez EC, Aunon PZ, Sanchez AR. Oral chemotherapy: potential benefits and limitations. Rev Oncol. 2004;6:335-40
[30] Gemalmaz A, Avşar G. Experiences During and After Cancer Diagnosis: A Qualitative Study. Journal of Nursery Education and Research. 2015;12:93-98. https://doi:10.5222/HEAD.2015.093 (Turkish)
[31] Tuncay T. Analysis of Disease Stories of Young Cancer Patients Based on Strenghthening Approach, Toplum ve Sosyal Hizmet Dergisi. 2009; 20(2);69-87 (Turkish)
[32] Denois VR, Poirson J, Nourissat A, Jacquin JP, Guastalla JP, Chauvin F. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. European Journal of Cancer Care. 2011; 20: 520-27. https://doi: 10.1111/j.1365-2354.2010.01212.x